Anti-HIV drug Lenacapavir shows 100% efficacy, no safety concerns in women: Study – Firstpost
 "Anti-HIV drug Lenacapavir shows 100% efficacy, no safety concerns in women: Study – Firstpost")
Lenacapavir, injectable twice a year, is developed by the US-based biopharmaceutical company Gilead Sciences, Inc. as a pre-exposure prophylaxis (PrEP) drug. These drugs prevent the spread of infection in people not yet exposed to the disease-causing agent read more An HIV-preventive drug showed 100 per cent efficacy and ”no safety concerns” in women, according to … Read more
